Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Adalimumab Biosimilars Near A Third

Executive Summary

Biosimilar adalimumab rivals to AbbVie’s Humira blockbuster continue to take market share in Germany, the latest market data demonstrates.


Advertisement

Related Content

Fresenius Nod In EU Adds To Crowded Adalimumab Market
German draft offers firms pro and cons
UK expects to save 75% from adalimumab rivals
Danish procurers hail 87% Humira discount
German funds select Imraldi due to price
Imraldi sets pace on German price cuts

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

GB139953

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel